CN103743616A - Diluent for blood analyzer - Google Patents
Diluent for blood analyzer Download PDFInfo
- Publication number
- CN103743616A CN103743616A CN201310704255.1A CN201310704255A CN103743616A CN 103743616 A CN103743616 A CN 103743616A CN 201310704255 A CN201310704255 A CN 201310704255A CN 103743616 A CN103743616 A CN 103743616A
- Authority
- CN
- China
- Prior art keywords
- blood
- dilution
- sample
- blood sample
- stable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses diluent for a blood analyzer. Each liter of the diluent for a blood analyzer comprises 5-10g of sodium chloride, 8-12g of sodium sulfate, 0.1-0.3g of edetic acid, 0.2-0.8g of potassium chloride, 1-3g of imidazole, 0.1-5g of purine compounds, 1-3g of preservatives, 0.01-0.1wt% polyoxyethylene alkyl ethers, and has the pH value of 6.0-8.0. The white blood cell classification property as well as the stability of MCV (mean corpuscular volume) and blood sample substances in a blood sample specimen can be kept by adopting the diluent for the blood analyzer, and meanwhile, when the environment temperature changes, the MCV value of a blood sample is still at the stable level; moreover, purine compounds are added in a reagent, so that the stability of blood cells in a pre-diluted sample is improved, and a white blood cell three-cent histogram is kept stable; and a reagent contains non-ionic surface active agents, and the osmotic pressure is adjusted, so that the red blood cell volume in the pre-diluted sample is kept keeps to stable.
Description
Technical field
The present invention relates to blood analyser reagent technical field, particularly a kind of blood analyser dilution.
Background technology
Blood cell analysis is the most frequently used project of clinical examination, generally by extracting the blood sample of human body, then blood cell analysis in blood sample is checked, comprise the parameters such as haemoglobin (HGB), red blood cell count(RBC) (RBC), white blood cell count(WBC) (WBC), platelet count (PLT), haematocrit (HCT), MCV (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin (MCHC).
And the blood sample extracting is carried out to above-mentioned parameter while measuring, due to blood sample, this easily solidifies in put procedure after extracting, cell protein or material composition chemical reaction easily occur and decompose, or after in vitro, problem is led etc. in death, causes blood examination accurately to carry out.Therefore, for maintaining the stability of blood sample after extracting, generally in blood sample, add dilution, in case Hemostatic Oral Liquid solidifies, substance decomposition, cell death etc.
The blood analysis of external medical institutions adopts vein anticoagulation as sample mostly, and the feature of dilution has been paid close attention to result stability and the reliability under whole blood mode.And domestic the facing of China adopts peripheral blood to dilute in advance as sample, and in long-time situation of placing, can also guarantee the stable of haemocyte, thereby guarantee the requirement of the problem of analysis result.With the prediluted sample of such dilution, along with the prolongation of standing time, the histogram distribution of leucocyte result just there will be obviously abnormal.Classification error as leukocytic in frequent appearance, or unclassified situation, for clinical diagnosis brings difficulty, even provide error message.Simultaneously along with the prolongation of standing time, the change of temperature, MCV also there will be variation, makes the mensuration of MCV occur error.To clinical diagnosis, make the mistake.
Existing blood dilution liquid, general by add the method for stabilizing agent in dilution formula, can make pre-dilution of blood liquid sample after placing a period of time, can further promote hive off sort feature and MCV stability of leucocyte three does not change, but effect is bad after placement certain hour, existing blood analyser cannot guarantee the problem of MCV and leukocyte differential count and stability with dilution simultaneously simultaneously.
Summary of the invention
Fundamental purpose of the present invention is in order to make up the problems referred to above, provides a kind of pre-dilution of blood liquid sample that makes after long-time placement, and hive off histogram and MCV of leucocyte three keeps stable blood analyser dilution.
The present invention proposes a kind of blood analyser dilution, and every liter of described blood analyser comprises with dilution: the polyoxyethylene alkyl ether of sodium chloride 5～10g, sodium sulphate 8～12g, edetate 0.1～0.3g, potassium chloride 0.2～0.8g, imidazoles 1～3g, purine compound 0.1～5g, antiseptic 1～3g, 0.01%～0.1% weight; PH value is 6.0～8.0.
Preferably, purine compound is MU or hypoxanthine.
Preferably, described edetate is EDTA-K
2.
Preferably, the hydroxyl value of described polyoxyethylene alkyl ether is between 50～60.
Preferably, described antiseptic is p-hydroxybenzoate and derivant thereof.
Preferably, every liter of described blood analyser comprises with dilution: EDTA-K
2the polyoxyethylene alkyl ether of 0.25g, imidazoles 1g, sodium chloride 6g, sodium sulphate 10g, potassium chloride 0.3g, MU 0.15g, antiseptic 2g, 0.02% weight, pH value is 7.0.
Preferably, every liter of described blood analyser comprises with dilution: EDTA-K
2the polyoxyethylene alkyl ether of 0.25g, imidazoles 1g, sodium chloride 6g, sodium sulphate 10g, potassium chloride 0.3g, antiseptic 2g, 0.02% weight, hypoxanthine 5g, pH value is 7.0.
Adopt blood analysis instrument dilution of the present invention can keep the stability of leukocyte differential count in blood sample and MCV and blood sample material, simultaneously after variation of ambient temperature the MCV value of blood sample still in stable level; And in reagent, add purine compound, and promoted the stability of blood cell in pre-diluted sample, make leucocyte three histogram that hives off keep stable; In reagent, go back non-ionic surfactant and adjust osmotic pressure, making the erythrocyte volume in pre-diluted sample keep stable.
Embodiment
Should be appreciated that specific embodiment described herein, only in order to explain the present invention, is not intended to limit the present invention.
The invention provides a kind of blood analyser dilution, each rises in diluting blood sample liquid and includes:
Sodium chloride 5～10g, sodium sulphate 8～12g, edetate (EDTA-M) 0.1～0.3g, potassium chloride 0.2～0.8g, imidazoles 1～3g, purine compound 0.1～5g, polyoxyethylene alkyl ether 0.01%～0.1%(weight), antiseptic 1～3g;
Wherein the pH value of diluting blood sample liquid is 6.0～8.0.
Blood analyser dilution of the present invention, can promote from many aspects the stability of blood sample composition, meet blood sample under pre-dilution mode and place after the long period, leukocyte differential count property preservation is constant, and it is stable that red blood cell MCV keeps, and do not vary with temperature and change.
In order to solve the diluting blood sample liquid of existing purine-containing and the diluting blood sample liquid of surfactant, cannot take into account leucocyte heap sort in three minutes and cell stability problem simultaneously, first above-mentioned blood analyser of the present invention adopts edetate in dilution (EDTA-M) with dilution, in its molecular structure of edetate, contain 6 coordination atoms, in adding blood sample to after can with blood sample in some nominal price ions (especially calcium, ferric ion) carry out chelating, form stable chelate, thereby stop blood clotting; Adopt edetate as anti-coagulants simultaneously, on blood count in blood sample almost without impact.Than being easier to, expect, the edetate adding as anti-coagulants must be the EDTA that can dissociate after water-soluble
4-the water soluble salt of monomer; Because if the edetate adding is itself the calcium, magnesium salts etc. of chelating, because chelate structure own is relatively stable, so after adding blood sample to, the more difficult EDTA that dissociates
4-monomer, thus so just cannot with blood in nominal price ion chelating realize the effect of anti-freezing.Therefore, as those skilled in the art, generally adopt Na, the K salt of EDTA, water-soluble effective and water-soluble after monomer all can dissociate out.
Simultaneously at the purine compound that is added with aforementioned proportion in dilution for blood analyser, purine compound can guarantee that for having the phagocytic and stronger leucocyte of metabolic the metabolism of leucocyte after in vitro is in foundation level, purine compound makes the maintenance level of the in vitro leukocyte differential count property preservation afterwards of blood sample in being similar to body as stabilizing agent, thereby keeps sort feature and the quantity of in blood sample, wrapping cell to stablize.
Further blood sample, after in vitro, wherein contains the more protein such as haemoglobin and other various nutrition nutrients, once touch air and bacterium, this material nutrient is very easy to occur corrupt decomposition so.And the in the situation that of there is no bacterial inhibitor in blood sample, once miscellaneous bacteria enters just, can start amount reproduction, thereby make the composition in blood sample that huge change occur, thereby cannot be re-used as the sample that cause of disease detects.In order to prevent this situation, the antiseptic that is added with aforementioned proportion in dilution for blood analyser of the present invention, the principle of its role in being added on food is similar, the one, guarantee material not by humic or corruption, further guarantee the stability of blood sample; Can also further stop miscellaneous bacteria to be grown, cause the detection of blood sample inaccurate simultaneously.Here antiseptic can adopt general antiseptic, because character and the composition of antiseptic is generally stable inhibition class, is all difficult to other reactions occur in blood sample and the negative interaction that loses effect or produce other; Therefore antiseptic of the present invention adopts general antiseptic.
In order further to guarantee the stability of MCV and the character of haemocyte, in diluting blood sample liquid, be added with above-mentioned sodium chloride 5～10g, sodium sulphate 8～12g, potassium chloride 0.2～0.8g, the effect of these neutral salt in dilution is further to guarantee the concentration of whole diluting blood sample liquid, thereby maintains the osmotic pressure of dilution; Reason has two: first these slaines can be at the surface enrichment of blood cell, thereby forms the stability that water power layer guarantees MCV; Secondly more importantly, these neutral salt can regulate the concentration of whole diluting blood sample liquid, and then the osmotic pressure of adjusting dilution, can maintain osmotic pressure 200～400mOsm/kg, the cell in blood sample just can, because thereby permeable pressure head water absorption and swelling inside and outside cell after dilution is dead, not avoid occurring " haemolysis " phenomenon so.
Further in order to guarantee homogeneity and the stability of the whole solution of dilution for blood analyser of the present invention, and the group that further guarantees each component materials in dilution is active, wherein at every liter of blood analyser with being also added with 0.01%～0.1%(percent by weight in dilution) polyoxyethylene alkyl ether.Polyoxyethylene alkyl ether contains more hydrophobic group, can be used as surfactant, after in adding blood sample to, except maintaining the osmotic pressure of blood sample and potential balance, further improve the stability of each cell and composition in blood sample, can also be further that diluting blood sample dilute solution afterwards presents stable water power layer, guarantee homogeneity and the stability of whole solution.
Simultaneously at the imidazoles 1～3g that has also been added with buffer action in dilution for above-mentioned blood analyser.Certainly, after adding after mentioned component, whole blood analyser roughly can maintain 7.0 with the pH value of dilution, certainly also may have deviation.Because blood sample is generally alkalescence, when the difference in pH value and human body is too large simultaneously, the easy sex change of protein, the material of blood sample also easily decomposes, and therefore can adopt and comprise above-mentioned Cl
-hydrochloric acid or contain Na
+naOH when pH value deviation is larger, finely tune in the scope of pH value to 6.0～8.0, thereby guarantee the stable of material in blood sample.
Above-mentioned purine compound of the present invention is generally selected MU, hypoxanthine in real process, and the polarity that these two kinds of materials contain purine bases is relatively good, and the most frequently used the most general.Certainly, based on similar principles adenine, guanine, also can be used as substitute, but these the two kinds general forms with nucleotide exist, cost and properties or MU and hypoxanthine comparative optimization.
Further, in the above-described embodiment, edetate preferably adopts EDTA-K
2, the sodium salt of EDTA and sylvite are all less on blood count impact, but sodium salt solubleness is starkly lower than dipotassium, sometimes affects anti-freezing effect, and other slaine anti-coagulants are not suitable for blood count.
Further, in the above-described embodiment, the hydroxyl value of above-mentioned polyoxyethylene alkyl ether is between 50～60.Hydroxyl value is as surface-active hydrophobic group, and the hydroxyl value of the preferred polyoxyethylene alkyl ether of the present invention is between 50～60, and when hydrophobicity higher than 60 time can further promote, the turbidity of solution increases, homogeneity variation; When lower than 50 time, the formed stable current potential complex of water delivery group is inadequate, and stability aspect is slightly poor.
Further, in the above-described embodiment, antiseptic is selected parabens (comprising p-hydroxybenzoate and derivant thereof), such material is as the antiseptic adopting in the present invention, comparing other benzoic acid, sorbic acid etc. as antiseptic, itself is neutral, does not affect the pH value of hemodilution solution, and its corrosion-resistant acid-base condition is also neutral, compares the required acid condition such as benzoic acid, sorbic acid and want gentle.And this class material this as neutrality, character is more stable.
Further, the preferred every liter of blood analyser of the present invention is with comprising EDTA-K in dilution
20.25g, imidazoles 1g, sodium chloride 6g, sodium sulphate 10g, potassium chloride 0.3g, MU 0.15g, polyoxyethylene alkyl ether 0.02%(weight), antiseptic 2g, and pH value controls 7.0.Adopt the blood analyser of this ratio to use in the effect of dilution after use, the character of blood sample is more stable, wherein relatively good in conjunction with effect between MU and other components, and holistic cost is lower.
The preferred every liter of blood analyser of the present invention is with comprising EDTA-K in dilution
20.25g, imidazoles 1g, sodium chloride 6g, sodium sulphate 10g, potassium chloride 0.3g, antiseptic 2g, polyoxyethylene alkyl ether 0.02%, hypoxanthine 5g, same PH controls 7.0.Adopt the blood analyser of this ratio with dilution in use, owing to adopting hypoxanthine, for leukocyte differential count characteristic, have good help, make leucocyte three histogram that hives off keep stable.
Below by example, upper technology of the present invention is described further.
According to each component shown in following table 1, configure required blood analyser dilution.
Table 1:
Get blood analyser in above-described embodiment 1,2,5 with dilution and now commercially available maximum Sysmex SF-3000 blood analysis instrument dilution carry out clinical blood sample analysis, its result is as following table 2.
Table 2:
From upper table 2, can draw, above-mentioned blood analysis instrument dilution of the present invention is compared universal commercially available Sysmex SF-3000 blood analysis instrument dilution, the statistical accuracy of its blood count will be got well, because commercially available prod dilution cannot guarantee for the stability of blood sample, haemocyte has varied bacteria growing, decomposition and swollen dead phenomenon, thus enumerative accuracy the present invention of the haemocyte in blood sample can accomplish more accurate.Meanwhile, during blood analysis instrument dilution of the present invention is used, to dilute in advance blood samples storage time long for peripheral blood, also can not produce the abnormal or unclassified problem of leukocyte differential count, simultaneously after variation of ambient temperature the MCV value of blood sample still in stable datum-plane; And in reagent, add purine compound, and increased the stability of blood cell in pre-diluted sample, make leucocyte three histogram that hives off keep stable; And by adding non-ionic surfactant and adjust osmotic pressure in reagent, making the erythrocyte volume in pre-diluted sample keep stable, MCV measured value is not because overlong time and temperature variation change.
The foregoing is only the preferred embodiments of the present invention; not thereby limit the scope of the claims of the present invention; every equivalent transformation that utilizes description of the present invention to do, or be directly or indirectly used in other relevant technical fields, be all in like manner included in scope of patent protection of the present invention.
Claims (7)
1. a blood analyser dilution, it is characterized in that, every liter of described blood analyser comprises with dilution: the polyoxyethylene alkyl ether of sodium chloride 5～10g, sodium sulphate 8～12g, edetate 0.1～0.3g, potassium chloride 0.2～0.8g, imidazoles 1～3g, purine compound 0.1～5g, antiseptic 1～3g, 0.01%～0.1% weight; PH value is 6.0～8.0.
2. blood analyser dilution as claimed in claim 1, is characterized in that, described purine compound is MU or hypoxanthine.
3. blood analyser dilution as claimed in claim 1 or 2, is characterized in that, described edetate is EDTA-K2.
4. blood analyser dilution as claimed in claim 1 or 2, is characterized in that, the hydroxyl value of described polyoxyethylene alkyl ether is between 50～60.
5. blood analyser dilution as claimed in claim 1 or 2, is characterized in that, described antiseptic is p-hydroxybenzoate and derivant thereof.
6. blood analyser dilution as claimed in claim 2, is characterized in that, every liter of described blood analyser comprises with dilution: EDTA-K
2the polyoxyethylene alkyl ether of 0.25g, imidazoles 1g, sodium chloride 6g, sodium sulphate 10g, potassium chloride 0.3g, MU 0.15g, antiseptic 2g, 0.02% weight, pH value is 7.0.
7. blood analyser dilution as claimed in claim 2, is characterized in that, every liter of described blood analyser comprises with dilution: EDTA-K
2the polyoxyethylene alkyl ether of 0.25g, imidazoles 1g, sodium chloride 6g, sodium sulphate 10g, potassium chloride 0.3g, antiseptic 2g, 0.02% weight, hypoxanthine 5g, pH value is 7.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310704255.1A CN103743616A (en) | 2013-12-19 | 2013-12-19 | Diluent for blood analyzer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310704255.1A CN103743616A (en) | 2013-12-19 | 2013-12-19 | Diluent for blood analyzer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103743616A true CN103743616A (en) | 2014-04-23 |
Family
ID=50500654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310704255.1A Pending CN103743616A (en) | 2013-12-19 | 2013-12-19 | Diluent for blood analyzer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103743616A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106969964A (en) * | 2017-02-23 | 2017-07-21 | 宁波美晶医疗技术有限公司 | The negative enrichment method and kit of rare cell in a kind of blood based on micro-fluidic and immune Magneto separate |
| CN108169468A (en) * | 2017-12-12 | 2018-06-15 | 山东兰桥医学科技有限公司 | A kind of dilution and its configuration method suitable for a variety of blood analysers |
| CN112067827A (en) * | 2020-11-16 | 2020-12-11 | 天津德祥生物技术有限公司 | Antibody diluent and blood type test card comprising same |
| CN112985966A (en) * | 2021-02-08 | 2021-06-18 | 桂林优利特医疗电子有限公司 | Diluent for analyzing urine visible components and preparation method thereof |
| CN113176134A (en) * | 2021-04-19 | 2021-07-27 | 广州普道医疗科技有限公司 | Diluent for analyzing blood cells and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008202A (en) * | 1988-11-29 | 1991-04-16 | Sequoia Turner Corporation | Blood diluent for red blood cell analysis |
| US6225124B1 (en) * | 1999-06-02 | 2001-05-01 | Sysmex Corporation | Diluting reagent and method compelling time-independent consistency in MCV assay |
| CN1548942A (en) * | 2003-05-09 | 2004-11-24 | 上海捷瑞医用试剂有限公司 | Diluent for blood cell analysis instrument |
| CN101451931A (en) * | 2007-12-04 | 2009-06-10 | 深圳迈瑞生物医疗电子股份有限公司 | Blood dilution liquid and its use method |
| CN101685050A (en) * | 2008-09-26 | 2010-03-31 | 希森美康株式会社 | Reagent for diluting blood sample and method for measuring mean corpuscular volume by using the same |
| CN101975850A (en) * | 2010-09-13 | 2011-02-16 | 南京卡博生物科技有限公司 | Diluent for blood cell analyzer |
-
2013
- 2013-12-19 CN CN201310704255.1A patent/CN103743616A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008202A (en) * | 1988-11-29 | 1991-04-16 | Sequoia Turner Corporation | Blood diluent for red blood cell analysis |
| US6225124B1 (en) * | 1999-06-02 | 2001-05-01 | Sysmex Corporation | Diluting reagent and method compelling time-independent consistency in MCV assay |
| CN1548942A (en) * | 2003-05-09 | 2004-11-24 | 上海捷瑞医用试剂有限公司 | Diluent for blood cell analysis instrument |
| CN101451931A (en) * | 2007-12-04 | 2009-06-10 | 深圳迈瑞生物医疗电子股份有限公司 | Blood dilution liquid and its use method |
| CN101685050A (en) * | 2008-09-26 | 2010-03-31 | 希森美康株式会社 | Reagent for diluting blood sample and method for measuring mean corpuscular volume by using the same |
| CN101975850A (en) * | 2010-09-13 | 2011-02-16 | 南京卡博生物科技有限公司 | Diluent for blood cell analyzer |
Non-Patent Citations (2)
| Title |
|---|
| 刘涤瑕 等: "末梢血预稀释与全血模式以及静脉血检测血常规的比较与分析", 《实用医技杂志》 * |
| 张惠兰 等: "血细胞分析时末梢血放置时间对结果的影响", 《吉林医学》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106969964A (en) * | 2017-02-23 | 2017-07-21 | 宁波美晶医疗技术有限公司 | The negative enrichment method and kit of rare cell in a kind of blood based on micro-fluidic and immune Magneto separate |
| CN106969964B (en) * | 2017-02-23 | 2020-02-18 | 宁波美晶医疗技术有限公司 | Negative phase enrichment method and kit for rare cells in blood based on micro-fluidic and immunomagnetic separation |
| CN108169468A (en) * | 2017-12-12 | 2018-06-15 | 山东兰桥医学科技有限公司 | A kind of dilution and its configuration method suitable for a variety of blood analysers |
| CN112067827A (en) * | 2020-11-16 | 2020-12-11 | 天津德祥生物技术有限公司 | Antibody diluent and blood type test card comprising same |
| CN112985966A (en) * | 2021-02-08 | 2021-06-18 | 桂林优利特医疗电子有限公司 | Diluent for analyzing urine visible components and preparation method thereof |
| CN113176134A (en) * | 2021-04-19 | 2021-07-27 | 广州普道医疗科技有限公司 | Diluent for analyzing blood cells and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103743616A (en) | Diluent for blood analyzer | |
| CA1117401A (en) | Multi-purpose blood diluent for use in electronic blood analysis instrumentation | |
| NO163426B (en) | LISING REAGENT AND METHOD OF LISING. | |
| CN101311725B (en) | WBC differential count quality control matter and method for making same | |
| JPS60501522A (en) | Reagent for whole blood dilution and hemolysis | |
| CN103336110A (en) | Whole blood quality control material and preparation method thereof | |
| WO2014187013A1 (en) | Reagent for processing trace whole blood and application thereof | |
| CN112889810B (en) | Human umbilical cord mesenchymal stem cell injection frozen stock solution and preparation method thereof | |
| CN103698501A (en) | Cyanide-free hemolytic agent | |
| CN101246158B (en) | Hemolytic agent for measuring white blood cell in hemocyte | |
| CN102435724A (en) | Quality control material and calibrator for calibrating blood cell analyzers and preparation method thereof | |
| CA1168561A (en) | Stabilized multi-purpose blood diluent | |
| Mather et al. | Effects of hemolysis on serum electrolyte values | |
| CN102620950B (en) | Platelet preserving agent | |
| EP3538898A1 (en) | Prothrombin time reagent comprising an iron chelator | |
| US20130280203A1 (en) | High stable non-ionic n-vinyl butyrolactam iodine and preparation method thereof | |
| Wise | Normal arterial blood gases and chemical components in the unanesthetized dog | |
| CN104107436A (en) | Preserving fluid used for preserving dog whole blood and applications thereof | |
| Rodgers et al. | Irreversibly sickled erythrocytes in sickle cell anemia: a quantitative reappraisal | |
| CN108169468B (en) | Diluent suitable for various blood analyzers and preparation method thereof | |
| Ramanaiah et al. | Formation of binary complexes of Pb (II), Cd (II) and Hg (II) with maleic acid in CTAB-water mixtures | |
| EP0986394B1 (en) | Anti-coagulation of blood, blood plasma or synovial fluid products | |
| CN105794767B (en) | A kind of Precerving liquid and its application process for preserving pig whole blood | |
| US4244837A (en) | Multi-purpose blood diluent for use in electronic blood analysis instrumentation | |
| CN110160941A (en) | Three classification reagent for hemocyte analyzers of one kind |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140423 |
|
| RJ01 | Rejection of invention patent application after publication |